RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies. RemAb Therapeutics is a European, multi-asset, preclinical-stage biopharmaceutical company located in Barcelona, Spain. Our mission is to become a leader in the field of providing solutions for Gram-negative infections. We expect to achieve this objective by introducing multiple advanced, stage of the art products and reach commercialization worldwide.
Target Market
Biotechnology
Product and Services
RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies. RemAb Therapeutics is a European, multi-asset, preclinical-stage biopharmaceutical company located in Barcelona, Spain. Our mission is to become a leader in the field of providing solutions for Gram-negative infections. We expect to achieve this objective by introducing multiple advanced, stage of the art products and reach commercialization worldwide.
